Clinical Trial Update: Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating tigecycline versus ceftriaxone for complicated intra-abdominal infections and community-acquired pneumonia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Community-acquired Pneumonia
• Complicated Intra-abdominal Infection

Drugs mentioned

• TYGACIL (tigecycline)
• ceftriaxone (ceftriaxone sodium)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Community Acquired Bacterial Pneumonia, Complicated Intra-Abdominal Infection | Phase 3 | Status: WITHDRAWN